PTH / parathyroid hormone (aa 32-65) Protein (GST Tag)

Parathyroid hormone Protein Datasheet

PTH / parathyroid hormone Protein Product Information

• Synonym: PTH1
• Protein Construction: A DNA sequence encoding the human PTH (P05062) (Ser 32-Phe 65) was fused with the GST tag at the N-terminus.
• Source: Human
• Expression Host: E.coli

PTH / parathyroid hormone Protein QC Testing

• Purity: > 96 % as determined by SDS-PAGE
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met
• Molecular Mass: The recombinant human PTH/GST chimera consists of 265 amino acids and has a predicted molecular mass of 31 kDa. It migrates as an approxiamtely 30 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH 7.5.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: PTH / parathyroid hormone protein

PTH / parathyroid hormone Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

PTH / parathyroid hormone Protein Description

Parathyroid hormone (PTH), parathormone or parathyrin, is secreted by the chief cells of the parathyroid glands as a polypeptide. PTH elevates calcium level by dissolving the salts in bone and preventing their renal excretion. PTH may stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells. Parathyroid hormone (PTH) has been proved to play a pivotal role in maintaining myocardial contractility as well as effective natriuresis, and possible pathogenic mechanisms contributing to heart failure secondary to hypocalcemia and hypoparathyroidism. With the increased population of preosteoblastic lineages and the osteoblastic activation, Parathyroid hormone (PTH) drives anabolism in bone. Experiments have recently reported that the absence of osteoclasts in c-fos(- / -) mice might hinder PTH-driven bone anabolism, and that osteoclastic presence may be necessary for full osteoblastic differentiation and enhanced bone formation seen after intermittent PTH administration. Alternatively, it was suggested that PTH administration inhibits sclerostin synthesis by osteocytes, thereby allowing for active bone formation. Taken together, Parathyroid hormone (PTH) affects bone cells in a dual pathway-mediating osteoblastic (preosteoblastic) activities or osteocytic synthesis of sclerostin. Defects in PTH are a cause of familial isolated hypoparathyroidism (FIH), also called autosomal dominant hypoparathyroidism or autosomal dominant hypocalcemia. FIH is characterized by hypocalcemia and hyperphosphatemia due to inadequate secretion of parathyroid hormone.

References

1. Bedi B. et al., 2012, Proc Natl Acad Sci. 109 (12): 725-33.
2. Hasegawa T. et al., 2012, Clin Calcium. 22 (3): 373-9.
3. Ito M. 2012, Clin Calcium. 22 (3): 335-41.